ArticleBMC cancer2023
Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 26 citations in OpenAlex.
- Chitosan/β-cyclodextrin nanocarriers enhance 5-fluorouracil efficacy against colorectal cancer via pH-responsive release and apoptosis modulation.Scientific reports · 2026Article
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- Article
- Yttrium oxide nanoparticles induce potent selective cytotoxicity in HeLa cervical cance cells through ROS-mediated genomic instability and mitochondrial apoptosis.Scientific reports · 2026Article
- Rare-Earth Elements at the Interface of Chemistry and Cancer Therapy.Molecules (Basel, Switzerland) · 2026Review
- Wnt Signaling Downregulation Mediates T Cell Apoptosis Following OKT3-Induced T Cell Activation in Preclinical Models.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Synthesis and cytotoxicity of novel cyanochalcones: induction of cell cycle arrest, apoptosis, and autophagy in HEP2 and MCF-7 cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exploration of the In Vitro and In Vivo Neuroprotective Effects of Several Polyphenolics on LPS-Induced Neuroinflammation.Biochemistry research international · 2026Article
- Influence of Yttrium (Y) Substitution in pH-Responsive 5‑Fluorouracil Delivery of Y-ZnO Nanoformulation.ACS omega · 2025Article
- Cicer arietinum extract as antitumor and protective agent against Ehrlich Solid Carcinoma-bearing mice.BMC complementary medicine and therapies · 2025Article
- Potent cytotoxicity and induction of ROS-mediated genomic instability, mitochondrial dysfunction, and apoptosis by YNaunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Intersection of ferroptosis and nanomaterials brings benefits to breast cancer.Cell biology and toxicology · 2025Review
- Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells.Scientific reports · 2025Article
- Article
- Potential Applications of Rare Earth Metal Nanoparticles in Biomedicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- YScientific reports · 2025Article
- Article
- Iron-Dependent Cell Death: Exploring Ferroptosis as a Unique Target in Triple-Negative Breast Cancer Management.Cancer management and research · 2025Review
- Yttrium oxide nanoparticles ameliorates calcium hydroxide and calcium titanate nanoparticles induced genomic DNA and mitochondrial damage, ROS generation and inflammation.Scientific reports · 2024Article
- Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is a lethal mammary carcinoma subtype that affects females and is associated with a worse prognosis. Chemotherapy is the only conventional therapy available for patients with TNBC due to the lack of therapeutic targets. Yttrium oxide (Y
methodsTransmission electron microscopy (TEM), X-ray diffraction, Zeta potential, and dynamic light scattering (DLS) were used to characterize the Y
resultsOur results indicate favorable physiochemical properties of Y
conclusionThis study suggests that Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.